Laura Coates outlines the findings from a phase 4 trial demonstrating that adalimumab introduction may be a better approach than methotrexate dose escalation among patients with psoriatic arthritis and an inadequate response to methotrexate (4:35).
04-06-2020 | EULAR 2020 | Conference coverage | Video